# Response to Journal of Hepatology

We thank Luo and colleagues for their interest and comments on our study [1].

While we agree that diabetes may influence hip fracture risk, we have not presented specific estimates for patients with diabetes (nor for patients with any other comorbidity likely to affect the risk of bone fracture). Rather, we acknowledge the impact of comorbidity by adjusting our risk estimates for the Charlson Comorbidity Index, an established scoring system for comorbidity. The Charlson index includes diabetes in its scoring system, and is a reasonable way of accounting for the effect of diabetes and up to 20 other comorbidities at the same time [2]. With regard to the effect of antidiabetic medication specifically mentioned, the cited review [3] concluded that a small increased fracture risk is apparent among patients on Glitazones (*Hazard ratio across reviewed studies ranged from 1.35 to 1.71*). Less than 5% of type 2 diabetes patients in England and Denmark are reported to be on these medications, hence this is unlikely to have affected our estimates of risk unduly [4,5].

We agree that fracture risk may be lower in patients with compensated as opposed to decompensated cirrhosis. However, our study did not aim to explore the differences in risk among people with “early stage” cirrhosis as implied by Luo and colleagues. Rather we focused on patients with clinically diagnosed cirrhosis in both England and Denmark. Our approach to identifying cirrhosis cases was based on a method that has been previously validated [6] to identify the mix of cirrhosis cases in both countries. Consequently, our study includes clinically diagnosed patients with either compensated or decompensated cirrhosis, and our cohort therefore represents the case mix seen in clinical practice in the UK and in Denmark.

Finally, with reference to the authors’ request to further understand the balance of demographic characteristics between the cirrhosis and control group, we would suggest they look at Table 1 of our manuscript in which both demographic and clinical characteristics of all Danish and English patients included in our study are displayed.

**References**

1. Otete H, Deleuran T, Fleming KM, Card T, Aithal GP, Jepsen P et al. Hip fracture risk in patients with alcoholic cirrhosis: A population-based study using English and Danish data. *J Hepatol* 2018;69:697-704.
2. M.E. Charlson, P. Pompei, K.L. Ales, C.R. MacKenzie. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*, 40 (1987), pp. 373-383.
3. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. *Endocr Rev* 2015;36:194-213.
4. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. *BMJ*. 2016:12;354:i3477.
5. Christensen, Diana Hedevang, Jørgen Rungby, and Reimar Wernich Thomsen. “Nationwide Trends in Glucose-Lowering Drug Use, Denmark, 1999–2014. *Clinical Epidemiology*8 (2016): 381–387.
6. Fleming, K.M., Aithal, G.P., Solaymani-Dodaran, M., Card, T.R., West, J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: A general population-based study**.***J Hepatol*. 2008;49:732–738.